Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Caspase activation assays

AE Alex J Eustace
NC Neil T Conlon
MM Martina S J McDermott
BB Brigid C Browne
PO Patrick O’Leary
FH Frankie A Holmes
VE Virginia Espina
LL Lance A Liotta
JO Joyce O’Shaughnessy
CG Clair Gallagher
LO Lorraine O’Driscoll
SR Sweta Rani
SM Stephen F Madden
NO Neil A O’Brien
CG Charles Ginther
DS Dennis Slamon
NW Naomi Walsh
WG William M Gallagher
RZ Radoslaw Zagozdzon
WW William R Watson
NO Norma O’Donovan
JC John Crown
request Request a Protocol
ask Ask a question
Favorite

1 × 104 cells were seeded per well and the cells were allowed to adhere overnight. 100 ng/mL TRAIL was added to the treatment group versus untreated control. Caspase 3/7, 8, and 9 activity were measured after 8 h incubations, using the Apotox-Glo™ Triplex assay, Caspase-Glo® 8, and Caspase-Glo® 9 assay kits and the GloMax®-Multi Microplate Multimode Reader (kits and equipment from Promega). Caspase 3/7, 8 and 9 activities were normalised against cell viability, which was determined using the GF-AFC Substrate Live Cell Assay (Triplex assay kit). Treatments were carried out using triplicate wells in each of three independent experiments.

Copyright and License information: The Author(s). ©2018
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A